Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Laser Photocoagulation of Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration-Reply

Laser Photocoagulation of Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular... Abstract In reply I thank Dr Hawkins for his most cordial and pertinent comments regarding my Editorial.1 Dr Hawkins was concerned that there might be a motivation on the part of the patients in the treated group for a better response to vision testing, and he wondered about the possibility of a sham form of therapy in the nontreated group to control for that possible effect. Given the ethical and administrative limitations and impracticalities of such therapy, given the unavailability of relevant motivational research to predict the possibility of bias in the treated vs the nontreated groups, and given the meticulous experimental design of the MPS, which included randomization, prospectivity, independent masked review, an elite core of clinical investigators, and a comparable prominent group composing the data and safety monitoring committees, I answer Dr Hawkins' question regarding to sham or not to sham by replying simply that there was, in References 1. Yannuzzi LA. A new standard of care for laser photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration: data revisited . Arch Ophthalmol . 1994;112:462-464.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Ophthalmology American Medical Association

Laser Photocoagulation of Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration-Reply

Archives of Ophthalmology , Volume 113 (5) – May 1, 1995

Laser Photocoagulation of Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration-Reply

Abstract

Abstract In reply I thank Dr Hawkins for his most cordial and pertinent comments regarding my Editorial.1 Dr Hawkins was concerned that there might be a motivation on the part of the patients in the treated group for a better response to vision testing, and he wondered about the possibility of a sham form of therapy in the nontreated group to control for that possible effect. Given the ethical and administrative limitations and impracticalities of such therapy, given the unavailability of...
Loading next page...
 
/lp/american-medical-association/laser-photocoagulation-of-subfoveal-choroidal-neovascularization-zt7k9lKkQ4
Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved.
ISSN
0003-9950
eISSN
1538-3687
DOI
10.1001/archopht.1995.01100050016008
Publisher site
See Article on Publisher Site

Abstract

Abstract In reply I thank Dr Hawkins for his most cordial and pertinent comments regarding my Editorial.1 Dr Hawkins was concerned that there might be a motivation on the part of the patients in the treated group for a better response to vision testing, and he wondered about the possibility of a sham form of therapy in the nontreated group to control for that possible effect. Given the ethical and administrative limitations and impracticalities of such therapy, given the unavailability of relevant motivational research to predict the possibility of bias in the treated vs the nontreated groups, and given the meticulous experimental design of the MPS, which included randomization, prospectivity, independent masked review, an elite core of clinical investigators, and a comparable prominent group composing the data and safety monitoring committees, I answer Dr Hawkins' question regarding to sham or not to sham by replying simply that there was, in References 1. Yannuzzi LA. A new standard of care for laser photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration: data revisited . Arch Ophthalmol . 1994;112:462-464.Crossref

Journal

Archives of OphthalmologyAmerican Medical Association

Published: May 1, 1995

References